Skip to main content
Premium Trial:

Request an Annual Quote

Cellular Dynamics, VivoMedica Launch Effort to Validate Cardiac Model

NEW YORK (GenomeWeb News) – Madison, Wis.-based Cellular Dynamics and Sittingbourne, England-based VivoMedica today said that they have launched a consortium to validate a human cell model and analysis system, based on the firms' technologies, for preclinical cardiotoxicity testing of drug candidates.

The firms said the consortium is being launched this week in France at the Safety Pharmacology Society 9th Annual Meeting. The firms hope to enlist pharmaceutical companies in validating the human cardiac model.

Specifically, the consortium aims to validate the testing system using Cellular Dynamics' iCell Cardiomyocytes and VivoMedica's DrugPrint analysis system. They said that extracellular micro-electrode array recordings from induced pluripotent stem cell-derived human cardiomyocytes will be analyzed using VivoMedica's electrical waveform analysis technology.

The partners believe this approach will identify drug-induced changes that indicate the arrhythmogenic potential of drug candidates under investigation.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.